Halozyme Therapeutics (HALO) Market Trends and Investment Opportunities Explored
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Market Insights: The latest Motley Fool Scoreboard episode features analysts discussing market dynamics surrounding Halozyme Therapeutics, providing unique insights into future investment opportunities that could help investors capitalize on potential gains.
- Investment Opportunity Assessment: The episode highlights Halozyme's innovative product line and competitive advantages in the biopharmaceutical sector, suggesting that these factors may attract more investor attention and drive stock price appreciation.
- Expert Analysis Sharing: Analysts participating in the discussion share their views on Halozyme's future, indicating that the company's ongoing investment in R&D will support its long-term growth in the market.
- Video Content Recommendation: Viewers are encouraged to watch the video for more market analysis and investment advice regarding Halozyme, further understanding the company's potential in the biotechnology field.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78.00 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 71.820
Low
56.00
Averages
78.00
High
92.00
Current: 71.820
Low
56.00
Averages
78.00
High
92.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
